This trial has completed recruitment on this platform, and is no longer accepting new referrals.
The Eclipse Trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1189, that may protect against mono. Participation in the Eclipse Trial lasts approximately 18 months, including a 28-day screening period, a six-month dosing period, and up to 11 months of follow-up observation.
Each year in the United States, there are approximately 500 cases of mono per 100,000 persons. Mono disproportionately affects adolescents and young adults from 15 to 24 years of age. There are currently no approved vaccines to protect against EBV and mono.
You will need to travel to one of the study sites taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin:
Participation in the Eclipse Clinical Trial lasts approximately 18 months and includes phone calls, telemedicine visits, and up to fifteen visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for participants’ time will be available.